Pet Supplement Compliance: The Complete Guide for Pet Product Brands

Why DSHEA Does Not Apply to Pet Supplements

When pet supplement brands use human supplement copy frameworks — structure/function claims with FDA disclaimers, "may help" qualifiers, or DSHEA-style benefit language — they are applying a legal framework that does not govern their products. This creates compliance exposure in two directions: the copy may not be protecting the brand in the way the brand believes, and the copy may be triggering veterinary drug regulations the brand doesn't know apply.

What the FDA Said in 1996

In April 1996, the FDA published a Federal Register notice responding to industry questions about whether DSHEA applied to supplements for pets. The FDA's answer was unambiguous: no. The DSHEA definition of "dietary supplement" specifies a product "intended for ingestion by a human being." Products intended for animals fall outside the statutory definition and are therefore outside DSHEA's regulatory framework.

This means:

• The FDA disclaimer — "These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease" — does not provide DSHEA protection for pet products
• DSHEA's structure/function claim framework does not apply to pet supplements
• Pet supplement brands cannot use DSHEA as a legal basis for any claim in their advertising

What Framework Actually Applies

Pet products in the US are regulated under a different framework, depending on what claims are made:

Animal food regulation (AAFCO): Pet supplements marketed without therapeutic claims are regulated as animal food products under FDA oversight and guided by AAFCO (Association of American Feed Control Officials) standards. They can make nutritional content claims — ingredient amounts, guaranteed analysis — but not therapeutic claims.

Veterinary drug regulation: If a pet supplement makes a claim that it diagnoses, treats, cures, or prevents a disease or health condition in animals, the FDA classifies it as a new animal drug under the Federal Food, Drug, and Cosmetic Act. New animal drugs require FDA approval through the Center for Veterinary Medicine (CVM) — a process equivalent in rigor to pharmaceutical drug approval for humans. No pet supplement brand has undergone this process.

The practical consequence: any therapeutic claim for a pet supplement in the US markets the product as an unapproved new animal drug — regardless of whether the brand believed DSHEA protected it.

The US Regulatory Framework for Pet Supplements

The NASC (National Animal Supplement Council) is the primary voluntary compliance organization for pet supplement brands in the US. While not a regulatory body, NASC membership requires brands to follow a Quality Seal program that includes adherence to specific advertising guidelines — guidelines that align with FDA CVM's own guidance on pet supplement claims.

FDA CVM Guidance on Pet Supplement Claims

The FDA CVM has not issued a comprehensive guidance document equivalent to the FTC's Health Products Compliance Guidance for human supplements. However, it has issued warning letters and enforcement guidance that establishes the following principles for pet supplement advertising:

• Nutritional content claims are acceptable: Claims about what the product contains — ingredient names and amounts — are factual statements that do not trigger drug classification
• Claims tied to specific health conditions in animals are drug claims: Any claim that implies a product treats, prevents, or alleviates a specific health condition in animals classifies the product as a new animal drug
• "Nutritional support for healthy [function] in healthy [animals]" — this framing is the most defensible for pet supplement benefit claims in the US market: anchoring to healthy animals and normal function rather than disease states

The NASC Claim Framework

NASC has developed specific guidance for member brands on permitted and prohibited claim language. NASC-compliant language focuses on: "nutritional support for" rather than "treats" or "helps"; specifying that claims apply to healthy animals; avoiding disease names; and including a NASC disclaimer: "This product is intended for intermittent or supplemental feeding only."

Permitted vs. Prohibited Claims: US Market

UK VMD Rules: The Strictest English-Language Market

The UK VMD's approach to pet supplement advertising is the strictest in any English-language market. The VMD's position is that any product marketed using language that implies it has a therapeutic effect on animals is a veterinary medicinal product (VMP) and requires VMD authorization.

The VMD's Trigger Words

The VMD has published guidance on words and phrases that it treats as indicating therapeutic intent. This list includes words that many brands use routinely in their advertising without realizing the VMD considers them veterinary medicinal product claims:

What Is Permitted in UK Pet Supplement Copy

In the UK, pet supplements (those that are not authorized veterinary medicinal products) should limit their claims to:

• Ingredient names and amounts: "Contains 500mg glucosamine per chew"
• Guaranteed analysis: protein, fat, fiber, moisture percentages
• Nutritional composition statements without condition or function claims
• Species and format information: "For dogs," "For cats," "Soft chew supplement"
• Quality and sourcing statements: "Wild-caught salmon oil," "Cold-pressed," "Free from artificial additives"

Any language beyond these categories risks the VMD classifying the product as a veterinary medicinal product — which would require VMD authorization that the brand does not have, making the product illegal to sell in the UK without that authorization.

Australia APVMA: "May Help" Has Zero Protection

Australia's approach to pet supplement regulation is particularly demanding because the APVMA's trigger for classifying a product as a veterinary chemical product is broad — it includes any claim that the product affects the structure or function of an animal, or that it prevents, treats, or alleviates any condition in animals.

The "May Help" Prohibition

The APVMA has specifically addressed the "may help" qualifier that many pet supplement brands use as a perceived compliance buffer. The APVMA's position is that "may help relieve joint stiffness in dogs" and "relieves joint stiffness in dogs" are equivalent from a regulatory classification standpoint. The qualifier does not change the nature of the claim — it merely adds linguistic uncertainty to a claim that implies therapeutic benefit.

This is the sharpest regulatory position on qualifiers in any market WriteLift serves. While the FTC in the US acknowledges that qualifiers don't automatically fix prohibited claims (the "net impression" standard), the APVMA's position is even more direct: specific qualifier words including "may help," "can help," "helps to," and "may assist" are on their list of phrases that indicate therapeutic intent and trigger APVMA regulation.

What Australian Pet Supplement Brands Can Say

For pet supplement brands selling in Australia without APVMA authorization, advertising must be limited to:

• Nutritional content claims tied to recognized nutrient requirements for the species
• Ingredient sourcing and quality information
• Palatability and convenience information
• General statements about the product being a "nutritional supplement for pets" without specific functional or health claims

Australian pet supplement brands selling products with therapeutic claims should seek APVMA advice on whether their products require authorization — the threshold for what constitutes a regulated claim is lower in Australia than in the US or UK, and many brands selling in Australia are technically selling unregistered veterinary chemical products without realizing it.

Canada Pet Supplement Rules

Canada's pet supplement regulatory framework sits between the US and UK/Australian approaches in terms of strictness. The Canadian Food Inspection Agency (CFIA) regulates feeds and supplements for animals, while Health Canada regulates human natural health products — notably, the Natural Health Products regulations that govern human supplements explicitly do not extend to products for animals.

For Canadian pet supplement brands, compliant copy focuses on nutritional content claims (ingredient amounts, guaranteed analysis) that align with recognized nutrient requirements for the target species, combined with factual sourcing and quality statements. Disease or health condition references trigger drug classification under the Food and Drugs Act, requiring federal approval that pet supplement brands do not hold.

The Highest-Risk Pet Supplement Claim Categories

Joint Health Supplements (Highest Risk)

Joint health is the most marketed and most-violated pet supplement category. The issue: buyers purchase joint supplements for dogs and cats with existing joint problems — arthritis, hip dysplasia, mobility issues — and brands respond by writing copy that speaks to those buyers' actual situations. The result is copy that makes therapeutic claims by referencing the conditions buyers have in mind.

The compliance challenge: you can acknowledge why buyers look for joint supplements without making condition-specific therapeutic claims. "Many pet owners choose joint supplements for dogs in their senior years" acknowledges the use case without claiming the product treats arthritis. "Nutritional support for healthy joints in active, aging dogs" acknowledges the life stage without naming a disease.

Anxiety and Calm Supplements

Calm and anxiety supplements represent a growing category with a distinct compliance problem: buyers are often managing diagnosed anxiety in their pets. Copy that uses "anxious dogs," "separation anxiety," "noise phobia," or "stress-related behavior" names conditions — some of which are veterinary diagnoses — making the product a veterinary drug claim in most markets.

Compliant calm supplement copy describes behavior contexts and nutritional components without naming conditions: "For dogs that benefit from calming nutrition before travel or fireworks" describes a situation without naming an anxiety disorder. "Contains L-theanine, known for its calming properties in humans, now formulated for dogs" stays in ingredient territory.

Immune Health Supplements

Immune health claims for pet supplements are prohibited in similar ways to human supplement immune claims — with the additional complication that in the UK, "boosts the immune system" is explicitly prohibited for human supplements and its equivalent for pets ("supports immune function," "immune booster for dogs") carries the same prohibition under VMD rules.

Skin Condition Supplements

"Helps itchy dogs," "for dogs with skin allergies," "relieves hotspots" — all of these describe health conditions (allergic dermatitis, contact dermatitis, pyoderma) and trigger veterinary drug classification. Compliant alternatives focus on ingredient content and healthy animal nutritional support: "Salmon oil — naturally rich in EPA and DHA for skin and coat nutrition."

What Actually Converts: Compliance-Safe Pet Copy

The misconception that compliance-safe pet supplement copy must be vague or unconvincing is directly contradicted by the evidence. The pet supplement buyer who researches products before purchasing — and they represent a significant and growing share of the premium pet supplement market — responds to specifics: ingredient amounts, sourcing transparency, manufacturing standards, and third-party testing. None of these require health claims.

The Four Pillars of High-Converting Compliant Pet Copy

1. Specific nutrient amounts: "Each soft chew contains: Glucosamine HCl 500mg | Chondroitin Sulfate 400mg | MSM 200mg." This is a Guaranteed Analysis-style presentation that is factual, compliant across all markets, and gives the ingredient-literate buyer exactly the comparison data they need.

2. Sourcing transparency: "Wild-caught Alaskan salmon — naturally rich in EPA and DHA omega-3s." "Single-source protein." "Human-grade ingredients." These are factual quality signals that do not require any health claims and resonate strongly with premium pet supplement buyers.

3. Third-party validation: "NASC Quality Seal." "Third-party tested for purity and potency." "Made in a GMP-certified facility." "COA available upon request." These signals address the purchase hesitation that stops first-time pet supplement buyers — the fear of low-quality or contaminated products.

4. Species and life stage specificity: "Formulated for large-breed dogs over 7 years." "For senior cats from age 8." "Soft chews — sized for medium breeds." This information is factual, compliance-safe, and helps buyers confirm they're purchasing the right product for their animal — which increases purchase confidence and reduces returns.

Amazon Pet Supplement Listing Rules

Amazon's pet supplement policy aligns with FDA CVM guidance: listings may not make claims that classify the product as an unapproved new animal drug. In practice, this means:

• Disease names in listing copy ("for dogs with arthritis") trigger compliance flags
• Therapeutic outcome language ("reduces joint pain," "eliminates anxiety") is prohibited
• Ingredient claims must accurately reflect the product's actual composition
• Testimonials describing improvement in diagnosed conditions should not appear in listing copy

Amazon's AI scanning system — the same system that enforces the March 2026 human supplement requirements — applies equivalent logic to pet supplement listings. The cross-platform scanning (Amazon listing plus external website) applies here as well. If a pet supplement brand's Shopify site says "helps dogs with hip dysplasia" and the Amazon listing is more conservative, Amazon's system may flag the external site claim and suppress the Amazon listing.

For more on Amazon's ingredient claim enforcement, see our guide to the Amazon March 2026 supplement deadline. For the complete picture of how FTC liability extends across the advertising supply chain, see our article on FTC copywriter liability.

Frequently Asked Questions